The Audit Committee and Board of Directors dismissed independent registered public accounting firm Forvis Mazars, LLP, effective after the filing of the quarterly report for the period ended September 30, 2026. The dismissal follows previously disclosed material weaknesses in internal control over financial reporting, including ineffective oversight of accounting transaction processing, lack of segregation of duties, deficiencies in IT general controls, and insufficient technical accounting expertise. Forvis Mazars's reports did not contain adverse opinions but included explanatory paragraphs regarding substantial doubt about the company’s ability to continue as a going concern. The company has not yet engaged a successor auditor. Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry.
